Technical advancement is moving at such a rapid pace that it can be challenging to define the tomorrow we’re working toward. In The Shape of Things to Come, Microsoft Research leader Doug Burger and experts from across disciplines tease out the thorniest AI issues facing technologists, policymakers, business decisionmakers, and other stakeholders today. The goal: to amplify the shared understanding needed to build a future in which the AI transition is a net positive.
Microsoft Principal Research Manager Ava Amini, Microsoft Chief Scientific Officer Eric Horvitz, and physician-scientist and Microsoft AI health advisor Eric Topol (opens in new tab) of Scripps Research join Burger to tackle a question with ramifications for every individual on the planet: What might the future of medicine look like with AI, and what needs to happen first?
Drawing from experiences in machine learning, bioscience, and clinical care, the group explores AI-assisted medical diagnosis, the untapped potential of leveraging AI in medical imaging, whole-patient models, virtual cells, and the role of biological foundation models in scientific discovery. The group also examines why promising research can be slow to reach patients, how AI could guide experiments and drug discovery, and why better biological data and real-world validation remain essential.
This episode delivers a research-grounded conversation of what AI can do today in the health space, the challenges and opportunities still ahead, and the shape of things to come.
Subscribe to the Microsoft Research Podcast:
Transcript
[MUSIC]
DOUG BURGER: This is The Shape of Things to Come, a Microsoft Research Podcast. I’m your host, Doug Burger. In this series, we’re going to venture to the bleeding edge of AI capabilities, dig down into the fundamentals, really try to understand them, and think about how these capabilities are going to change the world—for better and worse.
Today, I’m bringing three experts in the fields of biomedicine working on the frontlines of AI, biology, and medicine to see where healthcare is going, where the deep understanding of biology is going, what medical advances are coming, and how will AI change the future of health. These questions are really important because they will determine the shape of things to come.
[MUSIC FADES]
In today’s podcast, I’ve invited three leading researchers in medicine, biology, and machine learning/AI.
Eric Horvitz is Microsoft’s chief scientist [chief scientific officer] and is both a PhD and an MD. How you spent all those years in school, I have no idea. I’ve known Eric for decades and his work has shaped the entire field of machine learning. He’s a legend in the machine learning community and is a good friend.
Eric Topol is our second guest. He’s the executive vice president of Scripps Research (opens in new tab), the largest nonprofit biomedical research institute in the United States. He’s published over 1,300 peer-reviewed papers. Shocking, [LAUGHTER] shockingly productive. Authored four books (opens in new tab). So just an amazingly impressive, prolific scientist and physician.
Finally, Ava Amini is a principal research manager in Microsoft Research. She’s a rising star in our organization, an expert in the intersection of AI and precision medicine, and she’s a co-lead of Project Ex Vivo, a collaborative effort between Microsoft and the Broad Institute that is focusing on defining, engineering, and targeting cell states in cancer.
So thank you all for joining today. I think we’ve got a really, really amazing set of people, myself excluded. And I’d like to start to my guests here.
It’s clear there’s a huge disruption happening at the intersection of biology and medicine and AI right now. Just, you know, we’re seeing things, breakthroughs, happening at an accelerating pace. Models are helping us to discover structures and create abstractions that are really useful for moving forward the field of medicine. I’ve seen some recent talks where scientists with cancer used AI to design drugs for themselves. I mean, just unbelievable.
And today, I’ve got some long-term questions for us to discuss, maybe a little bit provocative. But I’d like to start with what each of you see as what’s happening right now, like, on the, on the intersection of medicine and biology and AI.
I think each of you has a unique vantage point. I’ll go around the horn, and I know, Eric, there’s a, you know, you have a cover article on Science magazine (opens in new tab) that’s really exciting, and so maybe you could talk a little bit about that, as well. So I’ll start with you, and then I’ll go to Eric Topol and then Ava.
ERIC HORVITZ: Thanks, Doug.
I think healthcare and the biosciences are fortunate disciplines as in that there’s been a digitalization of content—whether it be protein structure over, over decades, electronic health records, and so on—that makes these fields amenable to being at the ready for AI inferences and innovation. And therefore, I’ve been extremely optimistic about the long-term futures as well as what we’ll see early on at the frontiers of AI when it comes to the biosciences and healthcare.
Just extraordinary to see what’s happened over just the last five to eight years in the biosciences with both discriminative and generative AI models. You know, the AlphaFold (opens in new tab) breakthrough was tip of the iceberg, and we see just a whole, in some ways, a crest and a crashing of the wave of possibilities now when it comes to experimental platforms, experimental design, data interpretation in the biosciences, hypothesis generation, I should say, as a, as an assistant and a companion to scientific reasoners and human scientists.
In healthcare, we have an extraordinary opportunity to address long-term challenges in patient safety, in getting to timely diagnoses, in accessibility of healthcare. And after a couple of years of intensive work, I and just fabulous colleagues at Microsoft worked intensively on taking healthcare challenges when it comes to applications of AI and benchmarking—medical diagnostic challenges, for example—and moved it into what I would call the realm of medical cognition, where instead of looking at a whole case that’s given to an AI system and looking at the accuracies that are reported on its ability to diagnose, for example, a form of differential diagnosis, we instead put the AI system in the, in the shoes of a clinician.
You get an initial set of symptoms, you get chief complaint, some history, a little window on what’s going on when a patient comes in in an ambulatory setting, and then it’s up to the clinician to ask the right questions and to then think about tests, balancing the information value with the cost of the tests. This is the sequential diagnosis challenge. And we applied AI to both the … formulating the hypothesis component of that as well as decision-making about the next best tests to order, questions to ask, and also when to call a diagnosis, even under uncertainty, as a concluding convergent diagnosis and getting on with things with therapy, for example. And showed just, I think, remarkable abilities of a number of frontier language models to do a fabulous job.
And, you know, and again, did some comparisons with human generalist physicians, which have to be taken at face value and with limitations in what we did with … on the comparison, but still show the promise of the methods for assisting clinicians of the future.
BURGER: Well, congratulations on the paper. It’s a really big deal.
Eric [Topol], moving on to you. You know, you’re the one person on the podcast who’s not a Microsoft employee [LAUGHTER], and so you see a very different, I think, set of things than we might see from our vantage point, although I think each of the three of us sees different things in general.
Could you just tell us what you’re seeing? Like, to somebody listening, you know, we have a broad listenership from all different segments, not just experts in AI or medicine. Like, what are you seeing that your, sort of, technical, smart, average listener would be able to take away?
ERIC TOPOL: Yeah, sure, Doug. I mean, I think first I do also want to congratulate Eric and the team at Microsoft because this was a seminal paper in Science. It was the first ever to take an agentic system and make more accurate diagnoses not just compared with physicians but a lot of the other frontier models. Markedly improved accuracy over physicians, almost doubling, but at lower cost. I mean, that’s stuff we haven’t seen. What we’ve seen is, you know, using AI to upcode and using AI to potentially raise costs. This really was the first demonstration you could have higher accuracy at lower cost. It’s kind of like eat more, weigh less, [LAUGHTER] or taste better, you know. Anyway, it’s pretty impressive work.
Now,what I’ve seen, which is striking, is that we have all attuned to the shiny object of generative AI, which is great. It’s, you know, four years in. But we’ve somehow missed using where it’s even more proven, which is in the image phase, a deep learning of medical images. Whether it be the retina, chest x-ray, electrocardiogram, all these things.
And so there’s this real paradox where, for example, we aren’t implementing all that we’ve learned from mammography—over a hundred thousand women in a randomized trial (opens in new tab)—or colonoscopy—44 randomized trials (opens in new tab)—and eking out all the embedded information that humans can’t see, but AI can interpret from every type of medical image that we know of. So we’re not harvesting that opportunity.
Now, why is that important? Well, the next phase of AI is, you know, I guess, what I’d call whole-patient models, whereby we would have, as Eric mentioned, electronic health records; we’d have all the images, raw images, and other layers of data. It could be genomics, could be proteomics; it could be, you know, the exposome—all these layers of data.
But we can only get the most out of that at the individual level for being able to predict diseases and when they might occur and what-if scenarios if we change something to defer or prevent the disease and using these sorts of, you know, remarkable datasets to really change medical care in a way we’ve never done before. So I’m excited about that. But we are still idling. We haven’t used the work that’s been done to affect patient care. I’m still waiting for that to happen. It’s vexing to say the least.
BURGER: Just before I go on to Ava, you know, since you raised that, and what do you think the community should do differently so that we’re not missing that opportunity? I mean, there’s a ton of research going on; there’s a lot of work; there’s businesses adopting AI. What is the community missing?
TOPOL: Well, it’s missing implementation. So it all sits in these great journals and, you know, gone through a peer review and just impressive data, particularly these randomized trials that were done in the real world, and not used in caring for patients or helping patients.
So there’s no real good reasons why this hasn’t moved forward. There’s lots of excuses, [LAUGHTER] but, you know, the medical profession is slow to adopt change. Oftentimes, there’s financial constraints; there’s unwillingness to invest at health systems level because, you know, they’re working at very low margins …
BURGER: Right.
TOPOL: … and, you know, they don’t, they don’t want to get into something that they’re not fully confident with.
You know, the one thing that’s noteworthy is the physicians are not clamoring for these advances. I mean, if I—or the patients. If you’re a woman undergoing mammography and you don’t get state-of-the-art AI, which almost, you know, no women in the United States do, you think you might run a revolt. Or you have to pay for it to get that interpretation in a very limited network. There’s so many of these things that people are not getting … that either the physicians who advocate for patients or the patients themselves, maybe that’s what we need to drive this forward.
BURGER: I’m going to come back to that. That’s a really, I think, important point because it touches on just the economics of the system.
But, Ava, let me, let me turn to you. You’re deep in it, right? You’re playing with the models and working with, you know, outside organizations and actually pushing on, you know, disease states. So what are you seeing right now?
AVA AMINI: Yeah, from where I sit specifically, it’s at the intersection of AI and biology. So more focused on the biosciences versus medical and healthcare, but the perspective is very complementary to what Eric and Eric were both mentioning